2019
DOI: 10.1007/s10120-019-00941-z
|View full text |Cite
|
Sign up to set email alerts
|

Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501)

Abstract: Background The prognosis of patients with linitis plastica (type 4) and large (≥ 8 cm) ulcero-invasive-type (type 3) gastric cancer is extremely poor, even after extended surgery and adjuvant chemotherapy. Given the promising results of our previous phase II study evaluating neoadjuvant chemotherapy (NAC) with S-1 plus cisplatin (JCOG0210), we performed a phase III study to confirm the efficacy of NAC in these patients, with the safety and surgical results are presented here. Methods Eligible patients were ran… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
98
2
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 104 publications
(105 citation statements)
references
References 22 publications
(26 reference statements)
4
98
2
1
Order By: Relevance
“…In many Japanese institutions, SL is carried out based on the clinical trials of the Japan Clinical Oncology Group (JCOG). JCOG0501 is a randomized controlled trial evaluating the efficacy of neoadjuvant chemotherapy (NAC) for patients with large type 3 (≥8 cm) and type 4 advanced gastric cancer. JCOG 0405 is a phase II clinical trial evaluating the efficacy of NAC for GC patients with bulky lymph node metastases (≥3 cm) or para‐aortic node metastases (PAN).…”
Section: Resultsmentioning
confidence: 99%
“…In many Japanese institutions, SL is carried out based on the clinical trials of the Japan Clinical Oncology Group (JCOG). JCOG0501 is a randomized controlled trial evaluating the efficacy of neoadjuvant chemotherapy (NAC) for patients with large type 3 (≥8 cm) and type 4 advanced gastric cancer. JCOG 0405 is a phase II clinical trial evaluating the efficacy of NAC for GC patients with bulky lymph node metastases (≥3 cm) or para‐aortic node metastases (PAN).…”
Section: Resultsmentioning
confidence: 99%
“…(Table 3) In Japan, the standard treatment for locally advanced gastric cancer is surgery with postoperative adjuvant chemotherapy; however, the efficacy of preoperative neoadjuvant chemotherapy has also been investigated for selected patients with expected poor survival outcomes, such as those with scirrhous type (macroscopic type 4) gastric cancer or gastric cancer with extensive lymph node metastasis. The JCOG0501 is a multicenter randomized controlled trial aimed at demonstrating the efficacy of preoperative neoadjuvant chemotherapy with S-1 plus cisplatin for patients with type 4 or large type 3 (≥ 8 cm in maximum diameter) gastric cancer [30]. Unexpectedly, survival outcomes were similar in the two groups, with 3-year RFS rates of 60.9% and 62.4% for patients who received preoperative neoadjuvant chemotherapy versus those who did not, respectively (hazard ratio, 0.916; 95% CI, 0.679-1.236) [31].…”
Section: Standard Postoperative Adjuvant Chemotherapy In Japan (Table 2)mentioning
confidence: 99%
“…On the other hand, an ongoing Japanese trial (JCOG0501) compares their standard of care which is surgery followed by adjuvant S-1 chemotherapy, with neoadjuvant cisplatin and S-1 (an oral fluoropyrimidine) [15]. Although results of this trial are highly awaited, different tumor biology in the Japanese population makes it questionable whether they will be implemented in the Western population.…”
Section: Perioperative Chemotherapymentioning
confidence: 99%